Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents

American Journal of Medicine - United States
doi 10.1016/j.amjmed.2016.06.009
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Antithrombotic Drug and Its Clinical Indication. Factor Xa Inhibitor. Oral Xa Inhibitor (DX-9065a).

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1996English

Safety of 4-Factor Prothrombin Complex Concentrate (4f-Pcc) for Emergent Reversal of Factor Xa Inhibitors

Journal of Intensive Care
Critical CareIntensive Care Medicine
2018English

Dual HER2 Blockade: Preclinical and Clinical Data

Breast Cancer Research
Cancer ResearchOncology
2014English

Phosphatidylserine and Factor VA Regulate Factor Xa Structure

Biophysical Journal
Biophysics
2014English

Research and Development Strategy of Antithrombotic Agents: Pharmacology of the Oral Factor Xa-Inhibitor Edoxaban

Folia Pharmacologica Japonica
Pharmacology
2010English

Factor Xa Inhibitors

2016English

Reversal Agents for Use With Direct and Indirect Anticoagulants

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2016English

Synthetic, Universal Reversal Agent for Heparin Anticoagulants

Science-Business eXchange
2014English

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa Inhibitors

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy